整理 | GLP1减重宝典内容团队 银诺医药交出的2025年年报，最重要的意义不是把一组财务数据摆上台面，而是让市场第一次比较清楚地看到，这家公司已经从一家典型的港 股研发型Biotech，走到了有产品、有收入、有商业化网络、也有后续增长故事的新阶段。2025年，公司实现营业收入1.315亿元，全部来自核 心产品依苏帕格鲁肽α的销售；毛利达到1.17亿元，毛利率高达89.0%。对一家刚刚迈入商业化元年的创新药企而言，这意味着银诺已经完成了 最难的一步：把实验室里的核心资产，真正变成了市场上的现金流入口。 ▍首年破亿，真正值钱的不是收入本身，而是放量通道已经打开 依苏帕格鲁肽α在2025年1月获批用于2型糖尿病，2月就在中国内地上市，9月进入澳门市场。更关键的是，产品在2025年12月被纳入国家医保 目录，并于2026年1月1日起正式执行，同时还进入了国家基层糖尿病防治管理指南。这几件事叠加在一起，决定了银诺这次商业化并不是停留 在首发上市层面，而是已经把未来放量最关键的几道门槛连续打通。对任何一款GLP-1产品来说，能否进入医保、能否进入基层临床路径，直 接决定了它后续的渗透速度和销售天花板。银诺2025年的 ...

复旦大学附属中山医院 李小英教授团队 ，在国际顶尖医学期刊 JAMA 上发表了题为：《Tirzepatide for Weight Reduction in Chinese Adults With Obesity：The SURMOUNT-CN Randomized Clinical Trial》的研究论文。 评估 替泊尔肽（Tirzepatide） 治疗中国成年肥胖或超重及体重 相关合并症患者的减肥疗效和安全性。 整理 | GLP1减重宝典内容团队 ▍ 受试者接受替尔泊肽15 mg剂量在52周的治疗后，体重减轻了17.5%（16.1公斤） 这是 首个中国 多中心 替尔泊肽（Tirzepatide）治疗肥胖和超重的有效性和安全性研究（SURMOUNT-CN）。这项随机、双盲、安慰剂对照的3 期临床试验显示，替尔泊肽15 mg剂量组受试者在52周的治疗后， 体重较基线时减轻了17.5%（16.1公斤） ，这表明了替尔泊肽在中国的肥胖 或超重成年患者中可实现显著、有临床意义且安全的体重减轻。 2025年10月30日，礼来发布2025Q3业绩，第三季度营收176.01亿美元，同比增长54%。综合前两个季度的业绩来看 ...

整理 | GLP1减重宝典内容团队 3月23日，先为达生物再次向港交所递交上市申请。与首次递表时相比，这一次公司的资本故事已有明显变化：核心产品埃诺格鲁肽注射液已先 后获批2型糖尿病和超重或肥胖长期体重管理两项适应症，先为达从一家以研发为主的生物科技公司，正式走到商业化门口。 先为达成立于2017年，核心方向一直围绕代谢疾病创新药，重点押注GLP-1赛道。九年时间里，公司从偏向型GLP-1的技术研发，一路推进到 产品获批和资本市场再度闯关，路径已经从实验室延伸到市场端。 ▍ 核心产品落地，偏向型成为最大标签 先为达最受关注的产品，是埃诺格鲁肽注射液先维盈。该产品在今年1月获批2型糖尿病适应症，随后又在3月获批用于成人超重或肥胖患者的长 期体重管理，成为公司首款商业化产品。 这款药的最大特点，是其被定义为cAMP偏向型GLP-1受体激动剂。相比传统GLP-1药物，先为达希望通过偏向性激活，减少受体脱敏和部分不 良反应，在疗效持续性与耐受性之间取得更好的平衡。这也是公司在竞争激烈的GLP-1赛道中最核心的差异化标签。 从招股书披露的数据看，埃诺格鲁肽在减重和控糖两端都拿出了较有竞争力的结果。公司披露，其在中国超重 ...

General Mills, Inc. ( GIS ) has failed to meet expectations per the company’s last quarterly report, and investors have (arguably rightly) been pulling out. However, I believe we’ve reached the bottom or are at least approaching it. Given this, IMarkets rise and fall, booms come and go, and the world keeps ticking. Ultimately, I believe observing megatrends, as difficult as they can be to spot, let alone fully comprehend, can yield insights into the advance of human society, which in turn could pave the way ...

整理 | GLP1减重宝典内容团队 从减重角度看，这当然是药物发挥作用的一部分，但从营养角度看，这也意味着一个新的问题：当每日摄入总量减少之后，每一餐的营 养密度就变得更加重要。 随着 GLP-1 类药物在减重和血糖管理中的应用越来越广，围绕这一人群的饮食需求也开始受到关注。近来，美国市场上陆续出现 了"GLP-1 Friendly"这一概念，不少食品企业将部分产品标注为更适合 GLP-1 使用者，强调高蛋白、含纤维、分量较小或更易消化。这 一趋势表明，GLP-1 的影响已经从药物本身，延伸到了日常饮食和消费选择。但对于普通使用者而言，真正需要理解的重点并不只是哪 些产品被贴上了新标签，而是：在使用 GLP-1 之后，饮食为什么需要调整，以及究竟应该如何调整。 GLP-1 类药物之所以会改变饮食方式，首先是因为它会影响食欲和饱腹感。许多使用者会明显感觉到进食量下降，更容易提前产生饱腹 感，对零食或高热量食物的兴趣也有所减弱。 过去在食量相对正常的情况下，一两餐吃得不够均衡，往往不会立刻产生明显影响；但在用药后，如果整体摄入本就有限，仍然以较随 意的方式进食，就更容易出现蛋白质不足、膳食纤维摄入偏低、饮水不足等 ...

整理 | GLP1减重宝典内容团队 ▍当减重药都在让人少吃，Atrogi却想让身体更像在运动 在GLP-1几乎统治减重市场叙事的当下，大多数新药仍在围绕一个核心逻辑打转：压低食欲、减少热量摄入、尽快把体重降下来。但瑞典生物 技术公司Atrogi显然不想沿着这条主路走。它押注的ATR-258是一款口服、GRK2偏向性的β2受体激动剂，目标不是让患者吃不下，而是尽可能 复刻运动状态下肌肉和代谢系统发生的那套反应：促进葡萄糖进入骨骼肌、改善代谢、推动体成分向减脂保肌甚至增肌的方向变化。 公司3月18日宣布，ATR-258已完成首批受试者给药，正式进入一项为期8周的人体研究，这也意味着这条运动模拟药物路线开始真正接受临床 层面的检验。 ▍它真正瞄准的，不只是减肥，而是GLP-1留下的那块空白 Atrogi这条路线之所以值得关注，不在于又多了一款减重候选药，而在于它试图回答GLP-1热潮中一个越来越被反复提起的问题：体重是降下 来了，但肌肉怎么办。越来越多研究和市场讨论都在关注，GLP-1类药物减掉的并不全是脂肪，其中一部分是瘦体重。对很多患者而言，这不 只是身材问题，更关系到基础代谢、长期体重维持能力、衰弱风险以及老 ...

17 March 2026 Equity Research Report Pharmaron (300759 CH/3759 HK) A/H: Buy/Buy: Orforglipron project wins a milestone to China CDMO in global GLP-1 supply chain Strategic Lilly partnership announced; muted share price reaction reflects limited near-term revenue contribution. Pharmaron announced a USD200m collaboration with Eli Lilly on 11 March 2026 for the ex-US drug product (DP) manufacturing of Orforglipron, Lilly's oral GLP-1 receptor agonist. The agreement marks the first publicly confirmed CDMO partn ...

Josephs said he has spent 35 years in the pharmaceutical industry, including 32 years in the CDMO sector. He said he was drawn to Lifecore because significant capacity investments were already in place, the company had a strong quality track record, and the opportunity was to “fill” capacity and improve profitability.The second segment is sterile injectable contract manufacturing, where Lifecore produces sterile injectable products for other pharmaceutical companies across both development and commercial st ...

Summary of Stevanato Group Conference Call Company Overview - Stevanato Group has 70 years of operational excellence and is a leading player in the biopharmaceutical and diagnostic industry, providing mission-critical solutions [2][4] - The company operates through two segments: Biopharmaceutical and Diagnostic Solutions (88% of revenue) and Engineering (12% of revenue) [2] Core Business Insights - The company offers a full portfolio of pharmaceutical glass products, including cartridges, vials, and syringes, which are critical for drug delivery [2][3] - High-value products, such as Nexa prefilled syringes, have the highest marginality and are essential for meeting stringent performance requirements [3][5] - Stevanato Group has a strong market position, being a leader in pen cartridges and ready-to-use vials, and second in prefilled syringes [4] Financial Performance - In 2025, the company achieved a 9% growth on a constant currency basis, with high-value solutions growing approximately 30% year-over-year, representing about 46% of total revenue [5][6] - Revenue from GLP-1s accounted for approximately 19%-20% of total revenue, growing over 50% compared to 2024 [5] - The company expanded gross profit margin by 160 basis points and operating profit margin by 220 basis points compared to 2024 [6] - For fiscal year 2026, the company expects top-line growth of 8%-10% on a constant currency basis, with high-value solutions projected to represent 47%-48% of total revenue [6][10] Market Trends and Growth Drivers - The biologics market is identified as a key growth area, with a 40% increase in customers ordering high-value prefilled syringes in non-GLP-1 applications [6][20] - The company anticipates growth in the vial market, particularly in sterile vials, with a projected mid- to high-single-digit growth in 2026 [17] - The biosimilars market is also expected to grow significantly, especially in regions like India and China [20][21] Capacity Expansion and Investment - Stevanato Group is investing heavily in capacity expansion, with a capital expenditure target of around EUR 250 million in 2026, primarily for high-value solutions [35][36] - The company is ramping up production in its new facilities in Fishers and Latina, with a focus on sterile cartridges and Nexa syringes [30][36] - The Fishers plant is expected to be fully operational by 2028, while the Latina plant is ahead in ramp-up compared to Fishers [30] Competitive Positioning - The company believes it has gained share in the biologics market rather than competing directly with other companies [38] - Stevanato Group is focused on high-value products, with gross profit margins typically between 40%-70% [50] Challenges and Risks - The company faces temporary headwinds from unfavorable currency exchange rates and tariffs, which impacted profits in 2025 [6][8] - There is a noted slowdown in decision-making for new projects, which may affect the Engineering segment's performance in 2026 [46] Conclusion - Stevanato Group is well-positioned for future growth, driven by strong demand for high-value solutions and a robust pipeline in biologics and biosimilars, despite facing some market challenges and currency headwinds [7][10][46]

Core Viewpoint - The stock prices of Kanglong Chemical (300759) surged following the announcement of a strategic partnership with Eli Lilly, which plans to invest $3 billion over the next decade to expand its supply chain capacity in China, particularly focusing on the production of the oral GLP-1 receptor agonist orforglipron [1][3]. Group 1: Investment and Strategic Partnership - Eli Lilly announced a $3 billion investment to enhance its supply chain capacity in China, focusing on local production of oral solid formulations [1][3]. - The investment will involve both internal expansion and partnerships with local manufacturers, leveraging Eli Lilly's Suzhou factory for capacity collaboration [3]. - The initial phase of the partnership with Kanglong Chemical includes a $200 million investment to support its technical capabilities, with potential for future scale expansion [3]. Group 2: Market Impact and Financial Projections - Following the announcement, Kanglong Chemical's A-shares opened up 7.1% and peaked at over 8%, while H-shares rose over 13% [1][3]. - Kanglong Chemical is expected to benefit from this partnership, which is seen as a significant milestone for its CDMO (Contract Development and Manufacturing Organization) business [5]. - Financial forecasts indicate that Kanglong Chemical's net profit for 2025 is expected to decline by 6% to 10%, with projected net profit between 1.614 billion to 1.686 billion yuan, primarily due to a decrease in non-recurring gains [5]. Group 3: Product Focus and Market Position - The oral GLP-1 receptor agonist orforglipron is the first of its kind to be registered globally, with Eli Lilly submitting its application for the treatment of type 2 diabetes and obesity to the National Medical Products Administration in China by the end of 2025 [4]. - The investment aims to capture the growing market for oral GLP-1 medications in China, enhancing Eli Lilly's competitive advantage globally [5].